Renovaro BioSciences launches AI-based neurotoxin countermeasure initiative

Renovaro’s wholly owned subsidiary BioSymetrics has unveiled a proprietary AI-based zebrafish screening platform designed to rapidly identify medical countermeasures for neurotoxic chemical agents, including weaponized substances like Sarin. The platform has been integrated into Renovaro’s Defense Countermeasures Program, marking a strategic entry into the dual-use biotechnology and biodefense sector. Renovaro’s platform is anchored by advanced data preprocessing coupled with in vivo toxicity testing, creating a robust, end-to-end discovery pipeline bolstered by their recently announced patent, “Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions”. This IP milestone expands the company’s foundational portfolio, further protecting its machine learning infrastructure for multi-modal biomedical data integration and predictive analytics-core to its scalable drug discovery and diagnostics business.The AI-based platform which uses an inexpensive zebrafish-based model for validation of neurotoxicity predictions, delivers rapid, automated screening of over 1,000 compounds per week, significantly outpacing traditional animal models. It captures behavioural, cardiovascular, and muscular responses to neuroactive chemicals, enabling ML-driven compound triage and mechanism of action prediction. This capability is vital for both commercial CNS drug discovery and defense applications involving neurotoxic exposure.